APUNTES DE CIENCIA - hgucr

A R T Í C U L O E S P E C I A L
(76) van Akkooi AC, Nowecki ZI, Voit C, Schafer-
Hesterberg G, Michej W, de Wilt JH, et al. Sentinel
node tumor burden according to the Rotterdam
criteria is the most important prognostic factor
for survival in melanoma patients: a multicenter
study in 388 patients with positive sentinel
nodes. Ann Surg 2008 Dec;248(6):949-55.
(77) Voit CA, van Akkooi AC, Schafer-Hesterberg G,
Schoengen A, Schmitz PI, Sterry W, et al.
Rotterdam Criteria for sentinel node (SN) tumor
burden and the accuracy of ultrasound (US)-
guided fine-needle aspiration cytology (FNAC):
can US-guided FNAC replace SN staging in
patients with melanoma? J Clin Oncol 2009 Oct
20;27(30):4994-5000.
(78) Tejera-Vaquerizo A, Solis-Garcia E, Rios-Martin
JJ, Moreno-Ramirez D. [Primary cutaneous
melanoma: prognostic factors not included in the
classification of the American Joint Committee
on Cancer]. Actas Dermosifiliogr 2011
May;102(4):255-63.
with ipilimumab in patients with metastatic
melanoma. N Engl J Med 2010 Aug
19;363(8):711-23.
(83) Chapman PB, Hauschild A, Robert C, Haanen JB,
Ascierto P, Larkin J, et al. Improved Survival with
Vemurafenib in Melanoma with BRAF V600E
Mutation. N Engl J Med 2011 Jun 5.
(84) Mangas C, Paradelo C, Puig S, Gallardo F,
Marcoval J, Azon A, et al. [Initial evaluation,
diagnosis, staging, treatment, and follow-up of
patients with primary cutaneous malignant
melanoma. Consensus statement of the Network
of Catalan and Balearic Melanoma Centers].
Actas Dermosifiliogr 2010 Mar;101(2):129-42.
(85) van Akkooi AC, de Wilt JH, Verhoef C, Schmitz
PI, van Geel AN, Eggermont AM, et al. Clinical
relevance of melanoma micrometastases (